PeptiDream Inc. (4587.T)
- Previous Close
1,595.50 - Open
1,590.00 - Bid --
- Ask --
- Day's Range
1,572.00 - 1,624.50 - 52 Week Range
1,039.00 - 2,549.00 - Volume
856,100 - Avg. Volume
845,258 - Market Cap (intraday)
210.224B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
69.43 - EPS (TTM)
23.36 - Earnings Date May 14, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Jun 28, 2011
- 1y Target Est
2,700.00
PeptiDream Inc., a biopharmaceutical company, engages in the discovery and development of constrained peptides, small molecules, and peptide-drug conjugate therapeutics. The company develops its products based on its Peptide Discovery Platform System, a drug finding platform that enables the production of non-standard peptide libraries for the identification of potent and selective macrocyclic peptide candidates, which then can be developed into peptide-based, small molecule-based, peptide-drug conjugate, and multi-functional peptide conjugates -based therapeutics and diagnostics. Its development pipeline include PD-L1 indicated for oncology and currently under Ph1 clinical phase development stage; PD-L1 BMS-986229 indicated for oncology and currently under Ph1 clinical phase development stage; CD38 BHV-1100 + NK Cells indicated for multiple myeloma and currently under Ph1 clinical phase development stage; S2-protein PA-001 indicated for COVID-19 and currently under Ph1 clinical phase development stage; GhR AZP-3813 indicated for acromegaly/NET and currently under Ph1 clinical phase development stage; Glypican-3 indicated for liver cancer and currently under preclinical development stage; Myostatin indicated for DMD/muscle disorders and currently under preclinical development stage; TfR indicated for neuromuscular disorders and currently under preclinical development stage; c-Kit indicated for allergic condition and currently under preclinical development stage; c-Met currently under preclinical development stage; and HA-protein indicated for influenza and currently under preclinical development stage. The company, through its subsidiary PDRadiopharma Inc., is involved in the research, development, manufacture, sale, export, and import of various radiopharmaceutical and radio diagnostic products. PeptiDream Inc. was incorporated in 2006 and is based in Kawasaki, Japan.
www.peptidream.comRecent News: 4587.T
Performance Overview: 4587.T
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 4587.T
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 4587.T
Valuation Measures
Market Cap
210.22B
Enterprise Value
212.93B
Trailing P/E
69.38
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.33
Price/Book (mrq)
5.21
Enterprise Value/Revenue
7.42
Enterprise Value/EBITDA
23.56
Financial Highlights
Profitability and Income Statement
Profit Margin
10.57%
Return on Assets (ttm)
6.39%
Return on Equity (ttm)
8.39%
Revenue (ttm)
28.71B
Net Income Avi to Common (ttm)
3.04B
Diluted EPS (ttm)
23.36
Balance Sheet and Cash Flow
Total Cash (mrq)
19.51B
Total Debt/Equity (mrq)
56.50%
Levered Free Cash Flow (ttm)
15B
Research Analysis: 4587.T
Company Insights: 4587.T
4587.T does not have Company Insights